Search NLS News

AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Limited.

The collaboration combines Salipro Biotech's expertise and its Salipro platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug discovery programs for the generation of small molecule drugs.

Despite international turbulence and news of life sciences and research funding disruptions in the U.S., investment in innovative life sciences projects continues, according to Mala Valroy, an investment manager with Industrifonden, one of Sweden’s largest evergreen venture capital (VC) funds. 


The board of SyntheticMR has appointed Lena Åredal as the new CEO.

The two companies will advance the development of two blood-brain barrier (BBB)-crossing recombinant enzyme replacement therapies (ERT) for lysosomal storage disorders (LSD), including alpha-mannosidosis (aMann) and Krabbe disease (KD), ultra-rare diseases that affect the central nervous system.

25 new researchers from all over the world will hopefully arrive in Lund this autumn.

Malin Walfridsson, former Head of R&D at Nordic Biomarker, has joined the company as COO and Deputy CEO.

Based on new geroscience findings, many of the diseases that emerge later on in life could be prevented if the aging process could be slowed down.

Swedish Mavatar has announced the opening of its first US office and the upcoming commercial launch of its platform Mavatar Discovery.

The phase 2a proof-of-concept DELTA NEXT trial aims to evaluate the efficacy and safety of delgocitinib cream compared to cream vehicle in the treatment of adults with mild to severe Palmoplantar Pustulosis (PPP).